Pleural Effusion clinical trials at University of California Health
2 research studies open to eligible people
A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 18 years and up
The LTI-01-2001 study is a double-blind, placebo-controlled, Phase 2 study to evaluate LTI-01 (single-chain urokinase plasminogen activator, scuPA) in patients with infected, non-draining pleural effusions.
at UC Davis UCLA UCSD
Tunneled Pleural Catheters for Refractory Effusions Attributed to Congestive Heart Failure (TREAT-CHF) Trial
open to eligible people ages 18 years and up
Congestive heart disease (CHF) can frequently cause transudative pleural effusions, some of which do not completely resolve with diuretics alone. These effusions can cause significant morbidity, leading to ongoing dyspnea and hypoxia, resulting in additional office and hospital visits. TREAT-CHF is a randomized trial studying tunneled pleural catheter (TPC) versus standard medical management for the treatment recurrent symptomatic pleural effusions secondary to CHF that are refractory to maximal medical therapy. TREAT-CHF will study whether the addition of a TPC can improve quality of life and minimize health care utilization over the one year following insertion.
at UCLA
Our lead scientists for Pleural Effusion research studies include Catherine Oberg, MD George Cheng, MD Scott S. Oh, DO, FCCP, DAABIP Namita Sood.
Last updated: